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Iowa, USA
Inthepresentstudy,theauthorsexaminedwhethertreat-
ing streptozotocin-induced diabetic rats with the combina-
tion of α-lipoic acid and ﬁdarestat, an aldose reductase in-
hibitor, can promote the formation of dihydrolipoic acid
in diabetic animals and thereby enhance the efﬁcacy of
α-lipoic acid as monotherapy toward preventing diabetic
vascularandneuraldysfunction.Treatingdiabeticratswith
the combination of 0.25% α-lipoic acid (in the diet) and
ﬁdarestat (3 mg/kg body weight) prevented the diabetes-
induced slowing of motor nerve conduction velocity and
endoneurial blood ﬂow. This therapy also signiﬁcantly im-
proved acetylcholine-mediated vasodilation in epineurial
arterioles of the sciatic nerve compared to nontreated di-
abetic rats. Treating diabetic rats with 0.25% α-lipoic acid
and ﬁdarestat (3 mg/kg body weight) was equally or more
effectiveinpreventingvascularandneuraldysfunctionthan
was monotherapy of diabetic rats with higher doses of
α-lipoic acid or ﬁdarestat. Treating diabetic rats with the
combination of 0.25% α-lipoic acid and ﬁdarestat (3 mg/kg
body weight) signiﬁcantly improved several markers of ox-
idativestressandincreasedtheserumlevelsofbothα-lipoic
acidanddihydrolipoicacid.Thesestudiessuggestthatcom-
bination therapy consisting of α-lipoic acid and ﬁdarestat
maybemoreefﬁcaciousinpreventingdiabetes-inducedvas-
cularandneuraldysfunctioninperipheraltissuecompared
to monotherapy, which requires higher doses to be equally
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effective.Theeffectofthiscombinationtherapymayinpart
be due to the increased production and/or level of dihy-
drolipoic acid.
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Diabeticneuropathyisamultifactorialproblemlikelydueto
the poor control of hyperglycemia. Two of the hyperglycemia-
induced perturbations are increased oxidative stress and the
activation of the polyol pathway [1, 2]. In animal models of
diabetes, prevention of these defects by treatment with antioxi-
dants or aldose reductase inhibitors has been shown to improve
peripheral neuropathy [3–24].
Oxidative stress has been deﬁned as a disturbance in the
balance between the production of reactive oxygen species
(oxygen free radicals, i.e., hydroxyl radical [OH·], superoxide
anion [O·
2
−], and hydrogen peroxide [H2O2]) and antioxidant
defenses [25]. Oxidative stress and the damage that it causes
have been implicated in a wide variety of natural and patholog-
ical processes, including aging, cancer, diabetes, atheroscle-
rosis, neurological degeneration, schizophrenia, and autoim-
mune disorders such as arthritis [26]. Oxidative stress can be
derived from a variety of sources and includes events such as
the production of reactive oxygen species by NAD(P)H and
xanthine oxidases, uncoupled nitric oxide synthase, mitochon-
drial oxidative phosphorylation, ionizing radiation exposure,
and metabolism of exogenous compounds [26]. In addition to
thesesourcesofoxidativestress,adecreaseintheactivityofan-
tioxidant enzymes, such as superoxide dismutase, glutathione
peroxidase, and catalase, may contribute to oxidative stress in
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some disease states [27]. There is considerable evidence sug-
gesting that oxidative stress occurs during the course of dia-
betes mellitus and contributes to the development of vascular
and neural dysfunction [3–16]. Previously, we have shown that
acetylcholine-induced vasodilation by arterioles that provide
circulation to the region of the sciatic nerve is impaired early
in diabetes and is accompanied by a reduction of endoneurial
blood ﬂow (EBF) and an increase in superoxide levels in these
vessels [28, 29]. We have also demonstrated that α-lipoic acid
providesgoodprotectionagainstoxidativestressindiabeticrats
fora4-to6-weekduration,preventingbothvascularandneural
diabetes-induced impairments [30].
Studies from numerous laboratories have shown that treat-
ing diabetic rats with an aldose reductase inhibitor improves
nerve function as well as EBF [17–24]. Aldose reductase in-
hibitor treatments have also been shown to prevent the de-
pression of endothelium-dependent aortic relaxations induced
by diabetes and abnormalities in contraction, and improve
the synthesis of prostacyclin by the aorta of diabetic rats
[31–33]. Recently, Keegan and colleagues have demonstrated
that treating diabetic rats with the aldose reductase inhibitor
WAY121509 completely prevented the diabetes-induced de-
crease in acetylcholine-induced relaxation in the corpus cav-
ernosum vascular bed [34]. Previously, we have demonstrated
that treating streptozotocin-induced diabetic rats with an al-
dose reductase inhibitor prevented metabolic derangements in
the sciatic nerve, as well as the reduction of glutathione in the
lens,andsigniﬁcantlyimprovedendothelium-dependentvascu-
lar relaxation in epineurial arterioles of the sciatic nerve, motor
nerve conduction velocity (MNCV), and EBF.
α-Lipoic acid is a good metal chelator and is capable of
scavenging hydroxyl radicals, hypochlorous acid, and singlet
oxygen, but not superoxide or peroxyl radicals [35–38]. How-
ever, in its reduced form, as dihydrolipoic acid, it is a good
scavenger of superoxide and prevents initiation of lipid per-
oxidation [35–38]. In vivo, α-lipoic acid can be converted into
dihydrolipoicacid[37,38].ThisreactionrequireseitherNADH
viaamitochondrialpathwayorNADPHviacytosolicpathways
[38, 39]. The latter cofactor is reduced in diabetes due to the
increased ﬂux of glucose through the aldose reductase pathway
[40, 41]. In the present study, we sought to determine whether
combininganaldosereductaseinhibitorwithα-lipoicacidpro-
motes the formation of dihydrolipoic acid, thereby enhancing
the antioxidant potential of α-lipoic acid.
MATERIALS AND METHODS
Unless stated otherwise, all chemicals used in these
studies were obtained from Sigma Chemical (St. Louis, MO).
Fidarestat was a generous gift from Sanwa Kagaku Kenkyusho
(Japan).
Animals
Male Sprague-Dawley (Harlan Sprague-Dawley, Indiana-
polis, IN) rats, 8 to 9 weeks of age, were housed in a certi-
ﬁed animal care facility and food (Harlan Teklad, no. 7001,
Madison, WI) and water were provided ad libitum. All insti-
tutional and National Institutes of Health (NIH) guidelines for
use of animals were followed. Diabetes was induced by in-
travenously injecting streptozotocin (55 mg/kg in 0.9% NaCl,
adjusted to a pH 4.0 with 0.2 M sodium citrate). Control rats
were injected with vehicle alone. The rats were anesthetized
with halothane before injection. Diabetes was veriﬁed 48 hours
later by evaluating blood glucose levels with the use of glucose
oxidase reagent strips (Lifescan, Milpitas, CA). Rats having
blood glucose levels of 300 mg/dL (16.7 mM) or greater were
considered to be diabetic. At this time, the diabetic rats were
randomly divided into 7 groups. Three of the groups received
α-lipoic acid (DL-6,8-thioctic acid) as a dietary supplement
0.1%, 0.25%, and 0.5% by weight. A 4th group received ﬁ-
darestat, as a dietary supplement 3 mg/kg body weight (BW).
The 5th and 6th group received a combination of ﬁdarestat
(3 mg/kg BW) and 0.1% or 0.25%, α-lipoic acid by weight, re-
spectively, as a dietary supplement. The 7th group represented
the untreated diabetic group. In a separate experiment, another
group of diabetic rats were treated with ﬁdarestat (15 mg/kg
BW). Based on diabetic rats daily consumption, the amount
of α-lipoic acid received on a daily basis by diabetic rats fed
0.25% α-lipoic acid in the diet was 175 mg/kg/rat. In studies
conducted by Cameron and colleagues, rats were given race-
mate α-lipoic acid in the diet and the calculated daily dose that
the rats received was about 300 mg/kg/day [10]. The α-lipoic
acid and ﬁdarestat were added to a meal form of the diet that
was formed into pellets for feeding purposes. Analysis of the
diet containing α-lipoic acid revealed undetectable levels of di-
hydrolipoic acid. Control and untreated diabetic rats were fed
nonsupplemented pelleted rat chow. The chow was made in the
laboratory, dried in a vacuum oven, and stored refrigerated un-
til use. All studies were conducted approximately 4 to 5 weeks
after the veriﬁcation of diabetes.
Onthedayoftheexperiment,bloodglucoselevelwasdeter-
mined and the rats were anesthetized with Nembutal intraperi-
toneally (50 mg/kg, intraperitoneal [IP]; Abbott Laboratories,
North Chicago, IL). Following the determination of MNCV
and EBF, the abdominal aorta was isolated and occluded 1
to 2 cm above the branch of the common iliac artery. The
rat was then sacriﬁced by exsanguination, and body temper-
ature lowered with topical ice. Samples of the left sciatic nerve
were then taken for determination of Na+,K +-ATPase activity
and sorbitol, fructose, and myo-inositol content. For markers
of oxidative stress, we collected the lens for determination of
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of superoxide, and serum samples were collected for determi-
nation of thiobarbituric acid–reactive substances (TBARSs).
Motor Nerve Conduction Velocity
MNCVwasdeterminedaspreviouslydescribedusinganon-
invasiveprocedureinthesciatic-posteriortibialconductingsys-
tem in a temperature-controlled environment [28–30]. The left
sciatic nerve was stimulated ﬁrst at the sciatic notch and then
at the Achilles tendon. Stimulation consisted of single 0.2-ms
supramaximal (8 V) pulses through a bipolar electrode (Grass
S44 Stimulator, Grass Medical Instruments, Quincy, MA). The
evoked potentials were recorded from the interosseous muscle
with a unipolar platinum electrode and displayed on a digital
storageoscilloscope(model54600A;HewlettPackard,Rolling
Meadows, IL). MNCV was calculated by subtracting the distal
from the proximal latency measured in milliseconds from the
stimulus artifact of the take-off of the evoked potential and the
differencewasdividedintothedistancebetweenthe2stimulat-
ing electrodes measured in millimeters using a Vernier caliper.
The MNCV was reported in meters per second.
Endoneurial Blood Flow
ImmediatelyafterdeterminationofMNCV,sciaticnerveen-
doneurial nutritive blood ﬂow was determined as previously
described [28–30]. The trachea was intubated for mechanical
ventilation and a carotid cannula inserted to monitor mean ar-
terial blood pressure. Core temperature was monitored using a
rectalprobeandtemperatureregulatedbetween36◦Cand37◦C
usingaheatingpadandradiantheat.Therightsciaticnervewas
carefullyexposedbyasmallsurgicalincisionandthesurround-
ing skin sutured to a plastic ring. The isolated area was ﬁlled
withmineraloilat37◦Ctoadepthof1cmtominimizediffusion
of hydrogen gas from the nerve. The rats were then mechani-
cally ventilated. A glass insulated platinum microelectrode (tip
= 2 µm) was inserted into the sciatic nerve, proximal to the
trifurcation, and polarized at 0.25 V with respect to a reference
electrodeinsertedsubcutaneouslyintotheﬂankoftherat.Once
the recording had stabilized, the inspired air was modiﬁed to
contain 10% hydrogen gas and this gas ﬂow continued until the
hydrogen current recorded by the electrode had stabilized, in-
dicating equilibrium of the inspired air with arterial blood. The
hydrogen gas supply was then discontinued and the hydrogen
clearance curve recorded until a baseline was achieved. The
hydrogen clearance data were ﬁtted to a mono- or biexponen-
tial curve using commercial software (Prism; GraphPad, San
Diego, CA) and nutritive blood ﬂow, (mL/min/100 g), calcu-
lated using the equation described by Young [42], and vascu-
lar conductance (mL/min/100 g/mm Hg), determined by divid-
ing nutritive blood ﬂow by the average mean arterial blood
pressure. Two recordings were made for each rat at differ-
ent locations along the nerve and the ﬁnal blood ﬂow value
averaged.
Vascular Reactivity
Videomicroscopy was used to investigate in vitro vasodila-
tory responsiveness of arterioles vascularizing the region of the
sciatic nerve (branches of the superior gluteal and internal pu-
dendal arteries) as previously described [28–30]. The vessels
used for these studies were generally oriented longitudinally in
relation to the sciatic nerve; however, on occasion radially ori-
ented vessels were also used. No differences were observed in
acetylcholine-induced vasodilation based on the orientation of
the vessel to the sciatic nerve. The arterioles used in this study
shouldberegardedasepineurialratherthanperineurialvessels.
To isolate these vessels, the common iliac was exposed and
the branch points of the internal pudendal and superior gluteal
arteries identiﬁed. The vessels were then clamped, and tissue
containingthesevesselsanditsbranchesdissectedenbloc.The
block of tissue was immediately submerged in a cooled (4◦C),
oxygenated (20% O2,5 %C O 2, and 75% N2) Krebs Henseleit
physiological saline solution (PSS) of the following compo-
sition (in mM): NaCl 118, KCl 4.7, CaCl2 2.5, KH2PO4 1.2,
MgSO4 1.2, NaHCO3 20, Na2EDTA 0.026, and glucose 5.5.
Branches of the superior gluteal and internal pudendal arter-
ies (50 to 150 µm internal diameter and 2 mm in length) were
carefully dissected and trimmed of fat and connective tissue.
Both ends of the isolated vessel segment were cannulated with
glass micropipettes ﬁlled with PSS (4◦C), and secured with
10-0 nylon Ethilon monoﬁlament sutures (Ethicon, Cornelia,
GA). The pipettes were attached to a single pressure reservoir
(initially set at 0 mm Hg) under condition of no ﬂow. The or-
gan chamber containing the cannulated vessels was then trans-
ferred to the stage of an inverted microscope (CK2; Olympus,
Lake Success, NY). Attached to the microscope were a CCTV
camera (WV-BL200; Panasonic, Secaucus, NJ), video moni-
tor (Panasonic), and a video caliper (VIA-100 K; Boeckeler
Instruments, Tucson, AZ). The organ chamber was connected
to a rotary pump (Masterﬂex; Cole Parmer Instrument, Vernon
Hills,IL),whichcontinuouslycirculated37◦CoxygenatedPSS
at 30 mL/min. The pressure within the vessel was then slowly
increased to 40 mm Hg. At this pressure, we found that KCl
gavethemaximalconstrictorresponse.Therefore,allthestudies
were conducted at 40 mm Hg. Internal vessel diameter (reso-
lution of 2 µm) was measured by manually adjusting the video
micrometer. After 30 minutes’ equilibration, KCl was added to
the bath to test vessel viability. Vessels, which failed to con-
strict more than 30%, were discarded. After washing with PSS,
vessels were incubated for 30 minutes in PSS and then con-
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Ann Arbor, MI) to 30% to 50% of passive diameter. There
wasnosigniﬁcantdifferenceintheamountofU46619required
to induce constriction in control and diabetic vessels. Cumu-
lative concentration-response relationships were evaluated for
acetylcholine (10−8 to 10−4 M) using vessels from control and
diabetic rats. At the end of each acetylcholine dose-response
determination, sodium nitroprusside (10−4 M) was added to
determine maximal vasodilation.
Detection of Superoxide
Superoxide levels were measured using the aorta by
lucigenin-enhanced chemiluminescence as described previ-
ously [30]. Vessel segments were incubated in 0.5 mL
phosphate-bufferedsalinecontaininglucigenin(5µmol/L)and
afterwards, relative light units (RLUs) measured using a Zylux
FB12 luminometer. For these studies, chemiluminescence was
measuredfor5minutes.Backgroundactivitiesweredetermined
and subtracted and RLUs were normalized to surface area.
Sciatic Nerve Sorbitol, Fructose,
and myo-Inositol Content
Asamarkerofﬁdarestattreatmentefﬁcacy,thelevelsofsci-
aticnervesorbitol,fructose,andmyo-inositolweredetermined.
Brieﬂy, the tissue samples were boiled for 10 minutes in wa-
tercontainingα-D-methylmannopyranosideasaninternalstan-
dard and deproteinized with 0.5 mL each of 0.19 M Ba(OH)2
and 0.19 M ZnSO4. Following centrifugation, the supernatant
was collected, frozen, and lyophilized. Afterwards, the sam-
ples were derivatized and intracellular content of sorbitol and
myo-inositol determined by gas-liquid chromatography as pre-
viously described [28–30].
Additional Biological Parameters
Lens glutathione (GSH) and serum TBARS levels were
determined as additional markers of oxidative stress. Lens
glutathione levels were determined according to Lou and
colleagues [43]. Lens were weighed and homogenized in 1 mL
of cold 10% trichloroacetic acid and centrifuged for 15 min-
utes at 1000 × g. The supernatant (100 µL) was mixed with
0.89 mL of 1.0 M Tris, pH 8.2, and 0.02 M EDTA. After-
wards, 10 µL of dithionitrobenzene was added and change in
absorbance measured at 412 nm. A glutathione standard curve
(100 to 500 ng) was performed for each assay. The data were
recorded as µg/mg wet weight. TBARS level in serum was de-
termined by the method of Mihara and colleagues [44] as mod-
iﬁedbySimanandEriksson[45].Brieﬂy,200µLofserumwas
boiledin0.75mLofphosphoricacid(0.19M),0.25mLthiobar-
bituricacid(0.42mM),and0.3mLwaterfor60minutes.After-
wards,thesampleswereprecipitatedwithmethanol/NaOHand
centrifuged for 5 minutes. The supernatant was measured ﬂuo-
rometrically at excitation wavelength of 532 nm and emission
wavelengthof553nm.Standardswerepreparedbytheacidhy-
drolysis of 1,1,3,3-tetraethoxypropane. The data were reported
as µg/mL serum. Serum α-lipoic, acid and dihydrolipoic acid
levels were determined as described by Teichert and Preiss
[46]. Serum, 0.5 mL, was acidiﬁed with 3 mL 0.05 M HCl.
The acidiﬁed serum was then applied to a phenyl solid phase
extraction column, which was washed with methanol and pre-
equilibratedwith0.05MHCl.Thecolumnwasthenrinsedwith
4 mL 0.05 M HCl and eluted with 1:1 methanol:acetonitrile.
The sample was dried under nitrogen, resuspended in 100 µL
acetonitrileandinjectedontothehigh-performanceliquidchro-
matography (HPLC) column. Chromatography was carried out
usingaNeucleosilC-185-µ120A250×4-mmreversedphase
column.Thecolumnwaselutedisocraticallywith33%acetoni-
trile:67% 0.05 M potassium phosphate pH 2.9, at a ﬂow rate of
1 mL/min. The eluent was monitored amperometrically using
a glassy carbon electrode at a potential of 1.10 V. Concentra-
tions were determined by comparison to a standard curve. Di-
hydrolipoic acid is easily and quickly oxidized to α-lipoic acid,
so care must be taken to eliminate oxygen whenever possible.
All samples were treated identically and HPLC solvents were
sparged with, and stored under, helium.
Data Analysis
The results are presented as mean ± SE. Comparisons be-
tween the groups for MNCV; EBF; sciatic nerve Na+,K+-
ATPase activity; sciatic nerve sorbitol, fructose, and myo-
inositol content; and serum TBARS and lens glutathione levels
were conducted using a 1-way analysis of variance (ANOVA)
and Newman-Keuls test for multiple comparisons (Prism;
GraphPad). Dose-response curves for acetylcholine-induced
relaxation were compared using a 2-way repeated-measure
ANOVA with autoregressive covariance structure using proc
mixed program of SAS [28–30]. Whenever signiﬁcant interac-
tions were noted, speciﬁc treatment dose effects were analyzed
using a Bonferroni adjustment. A P value of less than .05 was
considered signiﬁcant.
RESULTS
Animal Statistics
DatainTable1provideinformationontheﬁnalbodyweight
and blood glucose level for the rats used in these studies. Blood
glucose level was signiﬁcantly increased in all diabetic rats and
the diabetic rats failed to gain weight compared to the control
rats. There was no signiﬁcant difference in blood glucose level
and ﬁnal body weight between the untreated diabetic rats and
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TABLE 1
Physiological parameters for control and diabetic rats
Final Blood glucose
Group n weight (g) (mmol/L)
Control 9 397 ± 18 5.1 ± 0.4
Diabetic 9 214 ± 17a 25.6 ± 0.5a
D + 0.1% LA 8 239 ± 22a 21.3 ± 1.5a
D + 0.25% LA 8 210 ± 16a 22.6 ± 1.3a
D + 0.5% LA 6 190 ± 20a 21.0 ± 0.7a
D + 0.1% LA + Fid 9 255 ± 17a 20.4 ± 1.1a
D + 0.25% LA + Fid 9 241 ± 15a 22.2 ± 1.4a
D + Fid (3 mg/kg BW) 10 262 ± 17a 24.9 ± 0.7a
D + Fid (15 mg/kg BW) 4 300 ± 12a 21.6 ± 1.3a
Note. Streptozotocin-induced diabetic rats (D) were treated with
0.1% to 0.5% α-lipoic acid (LA) in the diet and/or ﬁdarestat (Fid),
3mg/kgBW.Aseparatesetofdiabeticratswastreatedwith15mg/kg
BW ﬁdarestat. After 4 to 5 weeks of diabetes and with or without
treatment, the studies were performed. Data are presented as mean ±
SEM for each group.
aP < .05 compared to control.
Parameters of Oxidative Stress
SerumTBARSs,lensglutathione,andsuperoxidecontentof
the aorta were measured as markers of oxidative stress. Data in
Table2demonstratethatdiabetescausesasigniﬁcantincreasein
serumTBARSandaortasuperoxidelevelsandadecreaseinlens
glutathionelevel.Treatingdiabeticratswithα-lipoicacid(0.1%
TABLE 2
Determination of serum TBARS, lens GSH, aorta superoxide, and serum α-lipoic acid (LA) and dihydrolipoic acid (DHLA)
in control and diabetic rats
TBARS GSH Superoxide LA/DHLA
Group (µg/mL) (µg/mg wet wt) (RLU/min/mm2) (pmol/mL)
Control 0.39 ± 0.03 3.0 ± 0.3 1.99 ± 0.26 15.5 ± 2.1/1.9 ± 0.2
Diabetic 0.55 ± 0.03a 1.1 ± 0.1a 3.38 ± 0.26a 15.2 ± 2.2/1.0 ± 0.2
D + 0.1% LA 0.46 ± 0.05 1.1 ± 0.1a 1.94 ± 0.23b 15.4 ± 4.6/1.1 ± 0.2
D + 0.25% LA 0.40 ± 0.02b 1.2 ± 0.1a 1.68 ± 0.15b 12.7 ± 1.0/3.4 ± 0.3
D + 0.5% LA 0.45 ± 0.03 1.1 ± 0.1a 1.66 ± 0.12b 15.8 ± 0.8/3.3 ± 0.3
D + 0.1% LA + Fid 0.39 ± 0.03b,d 2.2 ± 0.3b,c 2.20 ± 0.33b 27.8 ± 4.3d/4.4 ± 0.5d
D + 0.25% LA + Fid 0.38 ± 0.02b,d 2.7 ± 0.4b,c,d 1.86 ± 0.19b 35.7 ± 2.6a,b,c,d/17.9 ± 2.1a,b,c,d
D + Fid (3 mg/kg BW) 0.59 ± 0.05a 1.5 ± 0.2a 2.28 ± 0.28b 9.6 ± 1.2/0.9 ± 0.3
D + Fid (15 mg/kg BW) 0.47 ± 0.09 3.7 ± 0.5b 2.30 ± 0.26b ND
Note. Treatment conditions and the number of experimental observations were the same as described in Table 1. Data are presented as the
mean ± SEM for each group. Data for aorta superoxide are presented as relative light units (RLU).
aP < .05 compared to control.
bP < .00 compared to untreated diabetic.
cP < .05 compared to D + LA.
dP < .05 compared to D + Fid (3 mg/kg).
ND = not determined.
to 0.5%) signiﬁcantly reduced superoxide in the aorta but had
no effect on lens glutathione level. Treating rats with α-lipoic
acid tended to reduce serum TBARS level but a signiﬁcant de-
creasefromdiabeticratswasonlyobservedwith0.25%α-lipoic
acid. Treating diabetic rats with ﬁdarestat alone at 3 mg/kg BW
or 15 mg/kg BW signiﬁcantly reduced aorta superoxide lev-
els but not to the same extent as observed with treatment of
α-lipoic acid. The low dose of ﬁdarestat had no effect on serum
TBARSorlensglutathionelevels.Incontrast,treatingratswith
15 mg/kg BW restored lens glutathione level to normal values
and partially corrected the diabetes-induced increase in serum
TBARS level. Treatment of diabetic rats with the combination
of 0.25% α-lipoic acid and ﬁdarestat, 3 mg/kg BW, signiﬁ-
cantly decreased aorta superoxide and serum TBARS level and
increased lens glutathione level. However, only the combina-
tion of 0.25% α-lipoic acid and 3 mg/kg BW ﬁdarestat was
more effective than monotherapy in restoring lens glutathione
level.DatainTable2alsopresentthechangesinserumα-lipoic
acid and dihydrolipoic acid levels. Treating diabetic rats with
α-lipoic acid (0.1% to 0.5%) did not signiﬁcantly increase
serum α-lipoic acid or dihydrolipoic acid levels compared to
controloruntreateddiabeticrats.Treatmentofdiabeticratswith
the combination of 0.25% α-lipoic acid and ﬁdarestat, 3 mg/kg
BW, caused a signiﬁcant increase in both serum α-lipoic acid
and dihydrolipoic acid levels compared to control, untreated
diabetic rats, or diabetic rats treated with 0.25% α-lipoic acid
or 3 mg/kg BW ﬁdarestat alone.128 M. A. YOREK ET AL.
TABLE 3
Determination of motor nerve conduction velocity (MNCV) and endoneurial blood
ﬂow (EBF) in control and diabetic rats
EBF nutritive/conductance
Group MNCV (m/s) mL/min/100 g mL/min/100 g/mm Hg
Control 56.7 ± 1.8 25.8 ± 5.7 0.195 ± 0.031
Diabetic 38.2 ± 1.1a 7.6 ± 1.1a 0.065 ± 0.011a
D + 0.1% LA 47.2 ± 2.2a,b 19.0 ± 4.3 0.144 ± 0.023
D + 0.25% LA 47.3 ± 2.3a,b 24.4 ± 4.4b 0.198 ± 0.026b
D + 0.5% LA 49.5 ± 1.5b 23.0 ± 2.4b 0.191 ± 0.044b
D + 0.1% LA + Fid 48.2 ± 2.2a,b 16.9 ± 2.9 0.125 ± 0.017
D + 0.25% LA + Fid 51.6 ± 1.5b 26.4 ± 4.2b 0.202 ± 0.013b
D + Fid (3 mg/kg BW) 48.7 ± 1.9a,b 16.1 ± 5.1 0.127 ± 0.031
D + Fid (15 mg/kg BW) 53.7 ± 1.4b 22.8 ± 4.1b 0.175 ± 0.013b
Note.Treatmentconditionsandthenumberofexperimentalobservationswerethesameasdescribed
in Table 1. Data are presented as the mean ± SEM.
aP < .05 compared to control.
bP < .05 compared to untreated diabetic.
Neural Parameters
Diabetes caused a signiﬁcant impairment in sciatic nerve
EBF and MNCV (Table 3). Treating diabetic rats with α-lipoic
acid (0.25% and 0.5%) or 15 mg/kg BW ﬁdarestat alone sig-
niﬁcantly improved sciatic nerve EBF compared to untreated
diabetic rats. Treating diabetic rats with 0.1% α-lipoic acid or
3 mg/kg BW ﬁdarestat did not signiﬁcantly improve sciatic
nerve EBF compared to untreated diabetic rats and the com-
bination therapy of α-lipoic acid and 3 mg/kg BW ﬁdarestat
was not signiﬁcantly more effective in improving sciatic nerve
EBF than monotherapy with α-lipoic acid. MNCV was signif-
icantly improved compared to untreated diabetic rats by either
the monotherapy of α-lipoic acid (0.1% to 0.5%) or ﬁdarestat
(3 or 15 mg/kg BW) or the combination therapy. The greatest
improvement was observed with the combination therapy of
0.25% α-lipoic acid and 3 mg/kg BW ﬁdarestat or 15 mg/kg
BW ﬁdarestat alone.
Vascular Reactivity of Epineurial Arterioles
of the Sciatic Nerve
Figures1to4providedataontheinﬂuenceofthesetreatment
strategiesonacetylcholine-mediatedvasodilationbyepineurial
arteriolesofthesciaticnerve.Wepreviouslyreportedthattreat-
ingstreptozotocin-induceddiabeticratswithα-lipoicacidusing
a prevention protocol prevented in a concentration-dependent
manner the diabetes-induced impairment in acetylcholine-
mediated vasodilation [30]. These results are conﬁrmed from
studies presented in Figure 1. Treating diabetic rats with
α-lipoic acid, 0.5%, was most effective in preventing the
diabetes-induced impairment in vasodilation mediated by
acetylcholine compared to diabetic rats treated with 0.1% and
0.25%α-lipoicacid.Wehadalsopreviouslyreportedthattreat-
ingdiabeticratswithanaldosereductaseinhibitorsigniﬁcantly
improved acetylcholine-mediated vasodilation in epineurial ar-
terioles of the sciatic nerve [47]. In these studies, we examined
the effect of the combination therapy of ﬁdarestat, an aldose re-
ductase inhibitor, and α-lipoic acid on acetylcholine-mediated
vasodilation in epineurial arterioles. In order to determine the
effect of this combination of treatments, the dose of ﬁdare-
stat (3 mg/kg BW) used in these studies was one that showed
minimal effect when used alone in improving vascular func-
tion, as evident by the small improvement in EBF (Table 3)
and acetylcholine-mediated vasodilation (Figure 2). In con-
trast, when a higher dose of ﬁdarestat was used (15 mg/kg
BW)intreatingdiabeticrats,theimprovementinacetylcholine-
mediated vasodilation was signiﬁcant compared to untreated
diabetic rats and diabetic rats treated with 3 mg/kg BW ﬁ-
darestat, and similar to the beneﬁts reported by us for sorbinil
treatment of diabetic rats [47]. Figures 3 and 4 show the data
for treating diabetic rats with 0.1% α-lipoic acid plus ﬁdare-
stat (3 mg/kg BW) and 0.25% α-lipoic acid plus ﬁdarestat
(3 mg/kg BW), respectively. Data in Figure 3 demonstrate
that treating diabetic rats with 0.1% α-lipoic acid alone has
minimal beneﬁt on preventing the diabetes-induced impair-
ment in acetylcholine-mediated vasodilation in epineurial arte-
rioles.Incontrast,combining0.1%α-lipoicacidwithﬁdarestat
(3 mg/kg BW) signiﬁcantly improves acetylcholine-mediated
vasodilationcomparedtodiabeticrats.However,acetylcholine-
mediated vasodilation in diabetic rats treated with 0.1%
α-lipoic acid with or without ﬁdarestat (3 mg/kg BW)
remained signiﬁcantly impaired compared to control rats.DIABETIC NEUROPATHY: EFFECT OF LIPOIC ACID AND FIDARESTAT 129
FIGURE 1
Determination of the effect of treatment of diabetic rats (Diab) with 0.1% to 0.5% α-lipoic acid (α-LA) on
acetylcholine-mediated vascular relaxation in epineurial arterioles of the sciatic nerve. Pressurized arterioles were preconstricted
with U46619 (30% to 50%), and incremental doses of acetylcholine were added to the bathing solution while the steady-state
vessel diameter was recorded. The number of experimental animals used in these studies was the same as that noted in Table 1.
 The response to acetylcholine was signiﬁcantly different compared to control; +the response to acetylcholine was signiﬁcantly
different compared to the untreated diabetic rats.
Treating diabetic rats with 0.25% α-lipoic acid signiﬁcantly
improved acetylcholine-mediated vasodilation in epineurial
arterioles and was more efﬁcacious than treatment with 0.1%
α-lipoic acid (Figure 4). Nonetheless, acetylcholine-mediated
vasodilation in epineurial arterioles from diabetic rats treated
with0.25%α-lipoicacidremainedsigniﬁcantlyimpairedcom-
pared to control rats. Treating diabetic rats with 0.25% α-lipoic
acid and ﬁdarestat (3 mg/kg BW) normalized acetylcholine-
mediated vasodilation in epineurial arterioles and was signiﬁ-
cantly improved compared to diabetic rats treated with 0.25%
α-lipoic acid alone. Furthermore, treating diabetic rats with
0.25% α-lipoic acid and ﬁdarestat (3 mg/kg BW) was more ef-
ﬁcaciousthantreatmentofdiabeticratswith0.5%α-lipoicacid
or 15 mg/kg BW ﬁdarestat in the diet alone on acetylcholine-
mediated vasodilation.
DISCUSSION
Previously, we had reported that treating streptozotocin-
induced diabetic rats with 0.5% α-lipoic acid provides max-
imum protection against diabetes-induced oxidative stress and
the development of vascular and neural dysfunction in periph-
eral tissues [30]. We have also reported that sorbinil, an al-
dose reductase inhibitor, partially prevents the development of
diabetes-induced vascular and neural defects but was not as ef-
ﬁcacious as antioxidant therapies [30, 47]. In the present study,
we found that combining these therapies maximizes the ben-
eﬁts in preventing diabetes-induced slowing of MNCV, EBF,
oxidative stress, and vascular dysfunction. The combination
of 0.25% α-lipoic acid (in the diet) and ﬁdarestat (3 mg/kg
BW)completelypreventedthediabetes-inducedimpairmentof
acetylcholine-mediated vascular relaxation in epineurial arte-
rioles of the sciatic nerve. This combination was more effec-
tive in preventing diabetes-induced vascular dysfunction than
monotherapy of either compound when given at higher doses.
One possible explanation for these results is that treatment
ofdiabeticratswithﬁdarestatincombinationwithα-lipoicacid
favors the formation of dihydrolipoic acid. α-Lipoic acid is a
goodmetalchelatorandiscapableofscavenginghydroxylradi-
cals,hypochlorousacid,andsingletoxygen,butnotsuperoxide130 M. A. YOREK ET AL.
FIGURE 2
Determination of the effect of treatment of diabetic rats (Diab) with ﬁdarestat (Fid) (3 mg/kg BW) or ﬁdarestat (15 mg/kg BW)
on acetylcholine-mediated vascular relaxation in epineurial arterioles of the sciatic nerve. Pressurized arterioles were
preconstricted with U46619 (30% to 50%), and incremental doses of acetylcholine were added to the bathing solution while the
steady-state vessel diameter was recorded. The number of experimental animals used in these studies was the same as that noted
in Table 1.  The response to acetylcholine was signiﬁcantly different compared to control; +the response to acetylcholine was
signiﬁcantly different compared to the untreated diabetic rats; ‡the response to acetylcholine was signiﬁcantly different compared
to the 3-mg/kg BW ﬁdarestat-treated diabetic rats.
or peroxyl radicals [35–38]. However, in its reduced form, as
dihydrolipoic acid, it is a good scavenger of superoxide and
prevents initiation of lipid peroxidation [35–38]. In vivo, the
conversion of α-lipoic acid to dihydrolipoic acid requires ei-
therNADHorNADPH[37,38].Inthemitochondria,preferen-
tially R(+)-α-lipoic acid is converted to dihydrolipoic acid by
the action of dihydrolipoamide dehydrogenase which requires
NADH [38, 39]. Both stereoisoforms of α-lipoic acid can be
reduced in the cytosol by glutathione reductase or thioredoxin
reductase,andbothrequireNADPH[38,39,48].Inneutrophils,
as well as rat heart, kidney, and brain, NADH-dependent re-
duction of α-lipoic acid is prominent, whereas with rat liver,
NADH- and NADPH-dependent pathways were about equally
active [38, 39]. In erythrocytes and endothelial cells, NADPH
is the primary reducing cofactor for α-lipoic acid [38, 49]. In
diabetes,NADPHlevelsarereducedduetotheincreasedﬂuxof
glucose through the aldose reductase pathway [40, 41]. There-
fore, blocking the aldose reductase pathway with aldose reduc-
tase inhibitors such as ﬁdarestat likely restores NADPH levels,
permitting the formation of dihydrolipoic acid. This explana-
tion is supported by our studies demonstrating that serum dihy-
drolipoic acid levels are increased in diabetic rats treated with
0.25% α-lipoic acid and ﬁdarestat (3 mg/kg BW). It is unlikely
that treating diabetic rats with ﬁdarestat would promote the
formation of dihydrolipoic acid by the mitochondrial pathway
becausedihydrolipoamidedehydrogenaserequiresNADH[38,
39, 50]. Interestingly, the level of α-lipoic acid in serum was
also increased in diabetic rats treated with 0.25% α-lipoic acid
and ﬁdarestat (3 mg/kg BW) compared to diabetic rats treated
with 0.25% α-lipoic acid alone. The reason for this is unknown
but could be due to increased stability of the metabolism of
α-lipoic acid in the presence of aldose reductase inhibition. We
do not know the cellular source of the increased serum levels
of dihydrolipoic acid observed in our studies or the content of
α-lipoic acid or dihydrolipoic acid existing in the various tis-
sues. The latter could have an impact on the serum levels of
either α-lipoic acid or dihydrolipoic acid if one or the other is
preferentially taken up by tissues.
For these studies, we used a low concentration of ﬁdarestat
in order to detect whether the combination of α-lipoic acid andDIABETIC NEUROPATHY: EFFECT OF LIPOIC ACID AND FIDARESTAT 131
FIGURE 3
Determination of the effect of treatment of diabetic rats (Diab) with 0.1% α-lipoic acid (α-LA) with or without ﬁdarestat (Fid)
(3 mg/kg BW) on acetylcholine-mediated vascular relaxation in epineurial arterioles of the sciatic nerve. Pressurized arterioles
were preconstricted with U46619 (30% to 50%), and incremental doses of acetylcholine were added to the bathing solution while
the steady-state vessel diameter was recorded. The number of experimental animals used in these studies was the same as that
noted in Table 1.  The response to acetylcholine was signiﬁcantly different compared to control; +the response to acetylcholine
was signiﬁcantly different compared to the untreated diabetic rats.
ﬁdarestat had additive effects on diabetes-induced vascular
and neural dysfunction. At 3 mg/kg BW of ﬁdarestat, fructose
and sorbitol formation from the aldose reductase pathway was
reduced by 75% and 70%, respectively, and in the sciatic nerve
of diabetic rats compared to the sciatic nerve from untreated
diabetic rats (data not shown). However, compared to control
animals, the levels of fructose and sorbitol in the sciatic nerve
from ﬁdarestat-treated (3 mg/kg BW) diabetic rats remained
signiﬁcantly increased. In contrast, treatment of diabetic rats
with 15 mg/kg BW ﬁdarestat normalized fructose and sorbitol
levels in the sciatic nerve (data not shown). Therefore, the dose
of ﬁdarestat used in the α-lipoic acid and ﬁdarestat combina-
tion studies was suboptimal based on efﬁcacy as determined by
fructose and sorbitol formation in the sciatic nerve of diabetic
rats. At 3 mg/kg BW, ﬁdarestat was also suboptimal in restor-
ing lens glutathione levels and was only partially effective in
preventing superoxide formation in the aorta. Treating diabetic
ratswith15mg/kgBWﬁdarestatnormalizedglutathionelevels
in the lens. These studies demonstrate that in addition to pro-
tecting glutathione production, treatment of diabetic rats with
ﬁdarestat in combination with α-lipoic acid may promote the
formation of dihydrolipoic acid. This result may explain the
antioxidant properties of aldose reductase inhibitors [51].
In these studies, the effect of α-lipoic acid and ﬁdarestat
treatment to protect EBF, MNCV, and lens glutathione lev-
els as well as reduce the generation of superoxide appeared
to be independent of any additive inﬂuence of the two treat-
ments. Independently, treatment of diabetic rats with α-lipoic
acid in a concentration-dependent manner improved EBF and
acetylcholine-mediated vasodilation in epineurial arterioles.
There appeared to be no concentration-dependent effect by
α-lipoic acid in improving MNCV. α-Lipoic acid at 0.1% in
the diet was nearly as effective as 0.5% α-lipoic acid in im-
proving MNCV. This suggests that the diabetes-induced de-
fect in MNCV may be due to several derangements and not
solely mediated by a reduction in EBF and impaired vascu-
lar reactivity. This is not a new concept, and lends support
to the idea that combination therapy may be the most effec-
tive means of preventing diabetic neuropathy. Treating diabetic
rats with 0.25% α-lipoic acid reduced the formation of super-
oxide in the aorta and serum TBARSs to the same degree as
the combination treatment of 0.25% α-lipoic acid and 3 mg/kg132 M. A. YOREK ET AL.
FIGURE 4
Determination of the effect of treatment of diabetic rats (Diab) with 0.25% α-lipoic acid (α-LA) with or without ﬁdarestat (Fid)
(3 mg/kg BW) on acetylcholine-mediated vascular relaxation in epineurial arterioles of the sciatic nerve. Pressurized arterioles
were preconstricted with U46619 (30–50%), and incremental doses of acetylcholine were added to the bathing solution while the
steady-state vessel diameter was recorded. The number of experimental animals used in these studies was the same as that noted
in Table 1.  The response to acetylcholine was signiﬁcantly different compared to control; +the response to acetylcholine was
signiﬁcantly different compared to the untreated diabetic rats; ‡the response to acetylcholine was signiﬁcantly different compared
to the 0.25% α-lipoic acid or ﬁdarestat (3 mg/kg BW)-treated diabetic rats.
ﬁdarestat.Inourstudies,treatingdiabeticratswithα-lipoicacid
alone had no effect on improving glutathione levels in the lens
[30]. These results differ from studies conducted by Stevens
and colleagues [52]. In those studies, treating diabetic rats with
100 mg/kg/day IP α-lipoic acid corrected glutathione levels in
thesciaticnerve.Inourstudies,ratsweretreatedwith0.25%α-
lipoic acid in the diet. Based on the average daily consumption,
ourratsreceivedabout175mg/kg/dayα-lipoicacid.Thediffer-
ence in these results could be due to glutathione measurements
being conducted in different tissues or the different delivery
methods for α-lipoic acid treatment. We did ﬁnd that treating
diabeticratswith15mg/kgﬁdarestatimprovedlensglutathione
levels. This is similar to the effect of sorbinil treatment of
diabetic rats on lens glutathione levels we reported previously
[47]. In these studies, there was a synergistic effect on improv-
ing lens glutathione levels when treating diabetic rats with the
combination of 0.25% α-lipoic acid and 3 mg/kg BW ﬁdare-
stat. Treatment of diabetic rats with ﬁdarestat (3 mg/kg BW)
alone independently improved EBF and MNCV, by 50% and
60%, respectively, and reduced superoxide formation in the
aorta. Furthermore, treating diabetic rats with 3 or 15 mg/kg
BW of ﬁdarestat had a concentration-dependent effect on im-
proving EBF, MNCV, and acetylcholine-mediated vasodilation
in epineurial arterioles. Taken together, our results imply that
somemarkersofoxidativestressandneuralfunctionaresigniﬁ-
cantly improved by monotherapy using α-lipoic acid; however,
the greatest beneﬁcial effects were observed on all markers of
oxidative stress and vascular function when the combination
treatment consisting of 0.25% α-lipoic acid and 3 mg/kg BW
ﬁdarestat was used.
In these studies, the combination of 0.25% α-lipoic acid
and ﬁdarestat (3 mg/kg BW) provided the most efﬁcient im-
provement in EBF, MNCV, and acetylcholine-mediated va-
sodilation in epineurial arterioles. There did not appear to be
any additive-like interaction of these compounds in correcting
EBF or MNCV, although the improvement of acetylcholine-
mediated vascular relaxation by epineurial arterioles from di-
abetic rats did demonstrate additive-like responsiveness to the
combinationtherapy.Treatingdiabeticratswith0.25%α-lipoic
acid and ﬁdarestat (3 mg/kg BW) signiﬁcantly improved va-
sodilation in response to acetylcholine compared to monother-
apy. In addition, the effectiveness of the combination therapyDIABETIC NEUROPATHY: EFFECT OF LIPOIC ACID AND FIDARESTAT 133
in improving vascular reactivity was greater than the improve-
ment observed with monotherapy when using the highest dose
of α-lipoic acid (0.5% in the diet) or ﬁdarestat (15 mg/kg BW).
Reportsofsynergisticinteractionsinthepreventionofdiabetes-
induced slowing of MNCV and reduction of EBF between
α-lipoic acid and γ-linolenic acid have previously appeared
[8,53].Theseinvestigationshavereportedthattreatingdiabetic
rats with a combination of an aldose reductase inhibitor and
angiotensin-convertingenzymeinhibitorhassynergisticeffects
ontheneurovascular[54].IthasbeenreportedthatbothMNCV
and EBF were normalized by this combination therapy [54].
In regard to vascular reactivity impaired by diabetes, Keegan
and colleagues have demonstrated that relaxation responses to
acetylcholine in the corpus cavernosum were reduced by about
40%bydiabetes[53].Treatingdiabeticratswitheitherα-lipoic
acid or γ-linolenic acid alone did not signiﬁcantly improve
this deﬁcit. However, when combination therapy was used, the
endothelium-dependent relaxation was fully corrected. The au-
thors concluded that α-lipoic acid and γ-linolenic acid interact
synergistically to improve nitric oxide–mediated neurogenic
and endothelium-dependent relaxation of corpus cavernosum
in experiment diabetes [53].
In summary, diabetic neuropathy is a multifactorial disor-
der and combination therapy may be the best approach in pre-
venting vascular and neural dysfunction. These studies provide
evidence that the combination of α-lipoic acid and ﬁdarestat
provideaneffectiveapproachfortreatmentofdiabeticvascular
andneuraldysfunction,andthatﬁdarestatmaypromotethefor-
mation of dihydrolipoic acid in the diabetic state, contributing
to a more effective treatment for impaired vascular relaxation
in diabetes.
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